DK1504088T3 - Bakteriofager egnede til behandling og forebyggelse af bakterielle infektioner - Google Patents

Bakteriofager egnede til behandling og forebyggelse af bakterielle infektioner

Info

Publication number
DK1504088T3
DK1504088T3 DK03744903T DK03744903T DK1504088T3 DK 1504088 T3 DK1504088 T3 DK 1504088T3 DK 03744903 T DK03744903 T DK 03744903T DK 03744903 T DK03744903 T DK 03744903T DK 1504088 T3 DK1504088 T3 DK 1504088T3
Authority
DK
Denmark
Prior art keywords
bacteriophages
bacterium
lysing
infecting
bacteria
Prior art date
Application number
DK03744903T
Other languages
Danish (da)
English (en)
Inventor
Faith Adelaide Burden
Liudmilla Pencheva Glancey
David Allan Hodgson
Nicholas Harold Mann
Mark Edward Rapson
Original Assignee
Univ Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0207021.7A external-priority patent/GB0207021D0/en
Application filed by Univ Warwick filed Critical Univ Warwick
Application granted granted Critical
Publication of DK1504088T3 publication Critical patent/DK1504088T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK03744903T 2002-03-25 2003-03-19 Bakteriofager egnede til behandling og forebyggelse af bakterielle infektioner DK1504088T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0207021.7A GB0207021D0 (en) 2002-03-25 2002-03-25 Anti-bacterial agents
US10/215,056 US20030180319A1 (en) 2002-03-23 2002-08-07 Antibacterial agents
PCT/GB2003/001190 WO2003080823A2 (en) 2002-03-25 2003-03-19 Bacteriophages useful for therapy and prophylaxis of bacterial infections

Publications (1)

Publication Number Publication Date
DK1504088T3 true DK1504088T3 (da) 2007-12-17

Family

ID=28456031

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03744903T DK1504088T3 (da) 2002-03-25 2003-03-19 Bakteriofager egnede til behandling og forebyggelse af bakterielle infektioner

Country Status (10)

Country Link
EP (1) EP1504088B1 (es)
JP (1) JP2005520545A (es)
CN (1) CN1643139A (es)
AT (1) ATE370228T1 (es)
AU (1) AU2003226499A1 (es)
CA (1) CA2479897A1 (es)
DE (1) DE60315636T2 (es)
DK (1) DK1504088T3 (es)
ES (1) ES2292996T3 (es)
WO (1) WO2003080823A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020240A1 (en) * 2003-10-06 2007-01-25 Gangagen, Inc. Defined dose therapeutic phage
US20060153811A1 (en) 2005-01-10 2006-07-13 Jackson Lee E Use of viruses and virus-resistant microorganisms for controlling microorganism populations
CA2614800C (en) * 2005-07-12 2018-10-30 The University Of Leeds Bacteriophage specifically for lysing propionibacterium acnes and uses thereof
JP5292278B2 (ja) * 2006-04-04 2013-09-18 サントル ナショナル ドゥ ラ ルシェルシュ スィヤンティフィック（セーエヌエルエス） バクテリオファージ組成物の製造方法およびファージ治療分野における方法
EP2197284B1 (en) * 2007-10-04 2017-04-12 AmpliPhi Biosciences Corporation Anti-bacterial compositions
GB0800149D0 (en) * 2008-01-04 2008-02-13 Novolytics Ltd Improved host range phage
US8840900B2 (en) * 2008-07-03 2014-09-23 The Rockefeller University Chimeric bacteriophage lysin with activity against Staphylococci bacteria
GB2466177A (en) * 2008-12-03 2010-06-16 Arab Science & Technology Found Bacteriophage selection and breeding
RU2580248C9 (ru) * 2009-02-06 2018-01-17 Текнофахе, Инвестигасао Э Десенвольвименто Эм Биотекнолохия, Са Бактериофаг, обладащий активностью против pseudomonas aeruginosa, белки бактериофага и способы их применения
US20130121967A1 (en) * 2010-06-08 2013-05-16 Robert Leah Bacteriophages for use against bacterial infections
JP6058540B2 (ja) * 2010-09-17 2017-01-11 テクニファー−インダストリア テクニカ ファーマシューティカ，エス．エー． 抗菌性ファージ、ファージペプチド、及びそれらの使用方法
AU2013235883B2 (en) * 2012-03-19 2018-01-04 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
CA3082772C (en) 2012-05-04 2023-05-02 Armata Pharmaceuticals, Inc. Therapeutic bacteriophage compositions
GB201402139D0 (en) 2014-02-07 2014-03-26 Fixed Phage Ltd Treatment of topical and systemic bacterial infections
WO2016066722A2 (en) * 2014-10-28 2016-05-06 Ian Humphery-Smith Bacteriophage combinations for human or animal therapy
CN110656093A (zh) * 2019-10-12 2020-01-07 山东省农业科学院畜牧兽医研究所 一种新型沙门氏菌噬菌体库及其应用
CN111826309A (zh) * 2020-06-30 2020-10-27 武汉合缘绿色生物股份有限公司 一种液体生物营养菌剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2251724A1 (en) * 1996-04-15 1997-10-23 Paul Averback Compositions containing bacteriophages and methods of using bacteriophages to treat infections
CA2430501A1 (en) * 2000-01-11 2001-07-19 Intralytix, Inc. Method for produce sanitation using bacteriophages

Also Published As

Publication number Publication date
WO2003080823A2 (en) 2003-10-02
CA2479897A1 (en) 2003-10-02
ATE370228T1 (de) 2007-09-15
AU2003226499A1 (en) 2003-10-08
EP1504088B1 (en) 2007-08-15
WO2003080823A8 (en) 2004-12-16
JP2005520545A (ja) 2005-07-14
WO2003080823A3 (en) 2003-12-11
DE60315636D1 (de) 2007-09-27
ES2292996T3 (es) 2008-03-16
EP1504088A2 (en) 2005-02-09
CN1643139A (zh) 2005-07-20
DE60315636T2 (de) 2008-05-08

Similar Documents

Publication Publication Date Title
DK1504088T3 (da) Bakteriofager egnede til behandling og forebyggelse af bakterielle infektioner
Dyson et al. Antibiotic resistance and typhoid
Torres-Barceló The disparate effects of bacteriophages on antibiotic-resistant bacteria
Maharjan et al. Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse
Baggesen et al. Characterization of Salmonella enterica serovar Typhimurium DT104 isolated from Denmark and comparison with isolates from Europe and the United States
Allen et al. Associations among antibiotic and phage resistance phenotypes in natural and clinical Escherichia coli isolates
Weiss et al. Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo
Mishra et al. Heparin mimics extracellular DNA in binding to cell surface-localized proteins and promoting Staphylococcus aureus biofilm formation
BR0208597A (pt) Meio de detecção de staphylococcus aureus e/ou estafilococos com coagulose positiva e método de identificação de bactéria (s) da espécie staphylococcus aureus em uma amostra
Shen et al. A linear plasmid-like prophage of Actinomyces odontolyticus promotes biofilm assembly
Månsson et al. Sequence types of Staphylococcus epidermidis associated with prosthetic joint infections are not present in the laminar airflow during prosthetic joint surgery
DE602005025404D1 (de) Impfstoff gegen pasteurella multocida
WO2017013217A3 (en) Genetic testing for predicting resistance of salmonella species against antimicrobial agents
WO2017013220A3 (en) Genetic testing for predicting resistance of serratia species against antimicrobial agents
DE69732709D1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
Banerjee et al. Trend and pattern of antimicrobial resistance in molluscan Vibrio species sourced to Canadian estuaries
NO20056100L (no) Nitrogeninneholdende heteroarylderivater
Kejela et al. High prevalence of MRSA and VRSA among inpatients of Mettu Karl referral hospital, southwest Ethiopia
DK1406642T3 (da) Fremgangsmåde til polyvalent bakteriofag-fremstilling til behandling af bakterielle infektioner
Adeoye-Isijola et al. Vancomycin intermediate resistant Staphylococcus aureus in the nasal cavity of asymptomatic individuals: a potential public health challenge
Pardo et al. Characteristics of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) strains isolated from skin and soft-tissue infections in Uruguay
Chakrawarti et al. Extended spectrum beta lactamases detection and multiple antibiotic resistance indexing of Escherichia coli from urine samples of patients from a referral hospital of eastern Nepal
Ansari et al. Antimicrobial resistant determination and prokaryotic expression of smpA gene of Acinetobacter baumannii isolated from admitted patients
Al-Saadi et al. Antibiogram susceptibility patterns of Staphylococcus aureus harboring of MecA gene and prevalence aminoglycoside modifying enzymes (AMEs) genes in Iraq
Dai et al. Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori